CTOR

Company Overview — What Does CITIUS ONCOLOGY, INC. Do?

Citius Oncology, Inc. (NASDAQ: CTOR) is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. In August 2024, the U.S. Food and Drug Administration (FDA) approved LYMPHIR™ (denileukin diftitox-cxdl), our targeted immune therapy for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Citius Oncology, Inc. is a majority-owned publicly-traded subsidiary of Citius Pharmaceuticals, Inc. CITIUS ONCOLOGY, INC. (CTOR) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Leonard Mazur. With a market capitalization of $57M, CTOR is one of the notable companies in the Healthcare sector.

CITIUS ONCOLOGY, INC. (CTOR) Stock Rating — Avoid (April 2026)

As of April 2026, CITIUS ONCOLOGY, INC. receives a Avoid rating with a composite score of 26.2/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CTOR ranks #4,238 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CITIUS ONCOLOGY, INC. ranks #762 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CTOR Stock Price and 52-Week Range

CITIUS ONCOLOGY, INC. (CTOR) currently trades at $0.64. The stock lost $0.02 (2.4%) in the most recent trading session. The 52-week high for CTOR is $6.19, which means the stock is currently trading -89.6% from its annual peak. The 52-week low is $0.59, putting the stock 9.4% above its annual trough. Recent trading volume was 47K shares, suggesting relatively thin trading activity.

Is CTOR Overvalued or Undervalued? — Valuation Analysis

CITIUS ONCOLOGY, INC. (CTOR) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.00x, versus the sector average of 2.75x. The price-to-sales ratio is 14.86x, compared to 1.66x for the average Healthcare stock.

At current multiples, CITIUS ONCOLOGY, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CITIUS ONCOLOGY, INC. Profitability — ROE, Margins, and Quality Score

CITIUS ONCOLOGY, INC. (CTOR) earns a quality factor score of 17/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -43.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -23.0% versus the sector average of -33.1%.

On a margin basis, CITIUS ONCOLOGY, INC. reports gross margins of 80.0%, compared to 71.5% for the sector. The operating margin is -133.2% (sector: -66.1%). Net profit margin stands at -140.3%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CTOR Debt, Balance Sheet, and Financial Health

CITIUS ONCOLOGY, INC. has a debt-to-equity ratio of 88.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 0.83x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $4M. Cash and equivalents stand at $4M.

CTOR has a beta of 1.19, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for CITIUS ONCOLOGY, INC. is 16/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CITIUS ONCOLOGY, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, CITIUS ONCOLOGY, INC. reported revenue of $4M and earnings per share (EPS) of $-0.06. Net income for the quarter was $-25M. Gross margin was 80.0%. Operating income came in at $-17M.

In Q1 2026, CITIUS ONCOLOGY, INC. reported revenue of $4M and earnings per share (EPS) of $-0.06. Net income for the quarter was $-6M. Gross margin was 80.0%. Operating income came in at $-5M.

In FY 2025, CITIUS ONCOLOGY, INC. reported revenue of $0 and earnings per share (EPS) of $-0.34. Net income for the quarter was $-25M. Operating income came in at $-24M.

In Q3 2025, CITIUS ONCOLOGY, INC. reported revenue of $0 and earnings per share (EPS) of $-0.08. Net income for the quarter was $-5M. Operating income came in at $-5M.

Over the past 8 quarters, CITIUS ONCOLOGY, INC. has reported varying levels of revenue. Investors analyzing CTOR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CTOR Dividend Yield and Income Analysis

CITIUS ONCOLOGY, INC. (CTOR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CTOR Momentum and Technical Analysis Profile

CITIUS ONCOLOGY, INC. (CTOR) has a momentum factor score of 32/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

CTOR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CITIUS ONCOLOGY, INC. (CTOR) ranks #762 out of 838 stocks based on the Blank Capital composite score. This places CTOR in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CTOR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CTOR vs S&P 500 (SPY) comparison to assess how CITIUS ONCOLOGY, INC. stacks up against the broader market across all factor dimensions.

CTOR Next Earnings Date

No upcoming earnings date has been announced for CITIUS ONCOLOGY, INC. (CTOR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CTOR? — Investment Thesis Summary

The quantitative profile for CITIUS ONCOLOGY, INC. suggests caution. The quality score of 17/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. Momentum is weak at 32/100, a headwind for near-term performance. High volatility (stability score 16/100) increases portfolio risk.

In summary, CITIUS ONCOLOGY, INC. (CTOR) earns a Avoid rating with a composite score of 26.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CTOR stock.

Related Resources for CTOR Investors

Explore more research and tools: CTOR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CTOR head-to-head with peers: CTOR vs AZN, CTOR vs SLGL, CTOR vs VMD.